Avid Bioservices Inc (CDMO)

[volgoat]

To test this hypothesis, the research team from UT Southwestern injected rats with human non-small cell lung cancer cells and monitored tumor growth. Rats were split into four groups three weeks after tumor implantation: untreated, radiation only, 2aG4 (rodent equivalent antibody to bavituximab) only, or radiation and 2aG4. After 184 days of treatment, the radiation+2aG4 group had a 100% survival rate and a 67% tumor eradication rate. In contrast, only 12.5% of untreated, 33% of 2aG4, and 43% of radiation rats survived, and these rats were tumor-free.

http://bionews-tx.com/news/2014/04/09/ut-southwestern-medical-center-scientists-present-on-anti-cancer-agent-bavituximab-at-aacr/